查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1961157

細胞轉染市場－全球產業規模、佔有率、趨勢、機會和預測：按方法、最終用戶、地區和競爭對手分類，2021-2031年

Cell Transfection Market - Global Industry Size, Share, Trends, Opportunity and Forecast, Segmented By Method, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球細胞轉染市場預計將從 2025 年的 20.8 億美元成長到 2031 年的 34.9 億美元，複合年成長率為 9.01%。

該市場涵蓋了多種技術、試劑和設備，用於將外來性核酸導入真核細胞，以達到基因表現修飾和蛋白質生產等目的。該領域的成長主要得益於生物製藥研發投資的激增以及細胞和基因治療生產業務的擴張。根據美國細胞與基因治療學會 (ASGCT) 預測，2024 年該領域的研究活動將顯著增加，其年會上提交的科學摘要數量將比前一年增加 12%。這項數據凸顯了對高效轉染調查方法日益成長的需求，以支持不斷成長的臨床前和轉化研究。

市場概覽
預測期 2027-2031
市場規模：2025年 20.8億美元
市場規模：2031年 34.9億美元
複合年成長率：2026-2031年 9.01%
成長最快的細分市場 電穿孔
最大的市場 北美洲

儘管市場呈現成長態勢，但標準轉染方法固有的細胞毒性和效率差異性仍構成重大挑戰。許多化學試劑和物理轉染技術已知會誘導細胞壓力和細胞死亡，尤其是在敏感的原代細胞中，這會損害實驗數據的完整性，並限制這些工具在先進治療研發中的實際應用。因此，如何克服這些限制——在確保基因轉移成功的同時維持細胞活力——仍然是致力於最佳化先進治療流程的研究人員和生產商面臨的關鍵挑戰。

市場促進因素

全球細胞和基因治療研發管線的快速擴張是細胞轉染市場的主要驅動力，也因此迫切需要能夠有效遞送遺傳物質的技術。隨著治療舉措從臨床前階段推進到商業化生產階段，生物製藥開發商需要可靠的轉染方法來確保病毒載體生產和細胞藥物設計的高度一致性。大量候選藥物的研發為這項活躍的研發進程提供了支持。根據美國細胞和基因治療學會 (ASGCT) 和 Citeline 於 2024 年 4 月發布的報告，全球有超過 4000 種基因、細胞和 RNA 療法正在研發中。因此，不斷擴展的研發管線推動了各種遞送流程所需的關鍵轉染試劑和電穿孔設備的持續供應。

同時，醫藥和生技領域研發投入的增加顯著推動了市場成長，主要企業積極投資建設新設施，以增強其藥物發現和生產能力。這些投資日益集中在利用轉染技術進行重組蛋白合成和基因組藥物開發的先進製造中心。例如，2024年10月，禮來公司宣布投資45億美元建立禮來醫藥鑄造廠（Lilly Medicine Foundry），該廠將整合研發和先進製造技術。這種基礎設施擴張的趨勢十分普遍。 DCAT價值鏈洞察公司在2024年12月發布的報告顯示，諾和諾德公司當年投資約68億美元用於擴展其全球生產網路，凸顯了對生物製程技術的工業規模需求。

市場挑戰

與標準轉染技術相關的細胞毒性和效率差異是阻礙全球細胞轉染市場擴張的重大障礙。這些技術難題導致基因傳遞的異質性和細胞活力的降低，顯著增加了先進治療藥物生產過程中批次缺陷的風險。當轉染試劑引起細胞毒性或未能達到所需的效力標準時，製造商將面臨高比例的不合格產品，造成巨大的經濟損失和生產週期延長。這種不可預測性是業務擴張的主要障礙，迫使企業將過多的資源投入到品管和製程改進，而非市場成長。

例如，在轉染過程中維持細胞完整性的挑戰是造成生產過程中損失的主要原因之一。根據美國臨床腫瘤學會2024年發布的商業化階段細胞療法生產數據，某些基因修飾療法的不合格率高達約28%，其中細胞活力低被認為是造成這些失敗的主要原因。如此高的失敗率凸顯了目前轉染方法固有的操作不穩定性，限制了該行業可靠地滿足生物製藥產品激增需求的能力。

市場趨勢

在市場上，非病毒脂質體奈米顆粒載體的應用日益受到重視，以解決病毒遞送系統固有的安全隱患和生產瓶頸。生物製藥開發公司正在迅速整合這些合成載體，與傳統病毒載體相比，它們具有更低的免疫抗原性，並能更有效率地放大mRNA和基因編輯有效載荷。這種向先進非病毒機制的策略轉變，正推動著專注於下一代遞送技術的公司獲得大量資本投資。例如，2024年3月，Capstan Therapeutics公司資金籌措，用於進一步開發其專有的標靶化脂質奈米顆粒（tLNP）平台，以進行體內免疫細胞修飾。這凸顯了業界對基於脂質的系統作為未來安全遞送複雜基因療法標準的信心。

同時，符合cGMP規範的可擴展電穿孔平台正成為主流，旨在維持高轉染效率的同時，滿足商業化生產中嚴格的監管標準。隨著治療計畫從藥物發現推進到臨床應用，企業正逐步以自動化物理性遞送系統取代人工操作。這確保了即使在大規模生產中也能保持性能穩定，並降低了批次間差異的風險。這種對檢驗的高通量儀器的日益依賴，得益於業界關鍵技術的應用。例如，2024年5月，MaxCyte與Legend Biotech達成了一項策略平台授權合約，授權後者使用MaxCyte的流式電穿孔技術開發一系列細胞療法。此類協議凸顯了標準化、自動化電穿孔工作流程在保障先進細胞療法供應鏈方面發揮的關鍵作用。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球細胞轉染市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 方法（電穿孔法、脂質體轉染法、磷酸鈣法、病毒載體法、其他）
    • 按最終用戶（學術研究機構、製藥和生物技術公司、合約研究組織等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美細胞轉染市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲細胞轉染市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區細胞轉染市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東與非洲細胞轉染市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美細胞轉染市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球細胞轉染市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Thermo Fisher Scientific, Inc.
  • Promega Corporation
  • Lonza Group AG
  • QIAGEN NV
  • F. Hoffmann-La Roche Ltd.
  • Bio-Rad Laboratories Inc.
  • Merck KGaA,
  • OriGene Technologies, Inc.
  • MaxCyte, Inc.
  • Polyplus-transfection SA

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23886

The Global Cell Transfection Market is projected to expand from USD 2.08 Billion in 2025 to USD 3.49 Billion by 2031, reflecting a compound annual growth rate of 9.01%. This market encompasses the diverse array of technologies, reagents, and instruments employed to deliver exogenous nucleic acids into eukaryotic cells for the purpose of modifying gene expression and producing proteins. The sector's growth is fundamentally underpinned by a surge in biopharmaceutical research investments and the operational scaling of cell and gene therapy manufacturing. According to the American Society of Gene & Cell Therapy, research activity in this domain intensified significantly in 2024, as demonstrated by a 12% rise in scientific abstracts presented at their annual meeting compared to the prior year. This statistic highlights the escalating necessity for effective transfection methodologies to sustain an increasing volume of pre-clinical and translational research.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.08 Billion
Market Size 2031USD 3.49 Billion
CAGR 2026-20319.01%
Fastest Growing SegmentElectroporation
Largest MarketNorth America

Despite this growth trajectory, the market encounters substantial hurdles related to the cytotoxicity and inconsistent efficiency characteristic of standard transfection methods. Many chemical reagents and physical delivery techniques are known to induce cellular stress or cell death, particularly within sensitive primary cells, which compromises the integrity of experimental data and limits the practical application of these tools in advanced therapeutic development. Consequently, addressing these limitations to preserve cell viability while ensuring successful gene delivery remains a critical concern for researchers and manufacturers aiming to optimize advanced therapeutic workflows.

Market Driver

The rapid broadening of the global cell and gene therapy pipeline acts as a primary catalyst for the cell transfection market, generating an urgent need for technologies that enable the effective delivery of genetic material. As therapeutic initiatives progress from preclinical stages to commercial-scale manufacturing, biopharmaceutical developers require reliable transfection methods to produce viral vectors and engineer cell-based medicines with high consistency. This intense development activity is underscored by the sheer volume of active candidates; according to an April 2024 report by the American Society of Gene & Cell Therapy and Citeline, there were over 4,000 gene, cell, and RNA therapies in development worldwide. Consequently, this expanding pipeline propels the sustained procurement of essential transfection reagents and electroporation instruments required for diverse delivery workflows.

Simultaneously, escalating investment in pharmaceutical and biotechnology R&D is significantly reinforcing market growth, with major industry leaders aggressively funding new facilities to bolster drug discovery and production capabilities. These financial commitments are increasingly focused on advanced manufacturing centers that employ transfection for recombinant protein synthesis and genomic medicine development. For instance, Eli Lilly announced a $4.5 billion investment in October 2024 to create the Lilly Medicine Foundry, a facility aimed at integrating research with advanced manufacturing. This trend of infrastructure expansion is widespread; in December 2024, DCAT Value Chain Insights reported that Novo Nordisk invested approximately $6.8 billion cumulatively that year to enlarge its global production network, highlighting the industrial-scale demand for bioprocessing technologies.

Market Challenge

The cytotoxicity and variable efficiency linked to standard transfection techniques represent a critical impediment that directly obstructs the expansion of the Global Cell Transfection Market. These technical shortcomings lead to inconsistent gene transfer and diminished cellular viability, which significantly elevates the risk of batch failure during the manufacturing of advanced therapies. When transfection reagents cause cellular toxicity or fail to achieve required potency standards, manufacturers face high rates of out-of-specification products, resulting in substantial financial setbacks and prolonged production schedules. This unpredictability creates a formidable barrier to scaling operations, compelling companies to divert excessive resources toward quality control and process repetition rather than market growth.

For example, the challenge of maintaining cell health during the transfection process is a leading cause of manufacturing attrition. Data from commercial-stage cell therapy production, as reported by the American Society of Clinical Oncology in 2024, indicated that out-of-specification rates for certain gene-modified therapies reached approximately 28%, with low cellular viability pinpointed as a primary driver of these failures. Such high failure rates highlight the operational volatility introduced by current transfection methods, thereby restricting the industry's ability to reliably satisfy the surging demand for biopharmaceutical products.

Market Trends

The market is increasingly prioritizing the adoption of non-viral lipid nanoparticle vectors to address the safety concerns and manufacturing bottlenecks inherent in viral delivery systems. Biopharmaceutical developers are rapidly integrating these synthetic carriers because they offer reduced immunogenicity and streamlined scalability for delivering mRNA and gene-editing payloads compared to traditional viral vectors. This strategic pivot toward advanced non-viral mechanisms is fueling substantial capital investment in companies focused on next-generation delivery technologies. For instance, Capstan Therapeutics secured $175 million in Series B financing in March 2024 specifically to further its proprietary targeted lipid nanoparticle (tLNP) platform for the in vivo engineering of immune cells, underscoring the industry's confidence in lipid-based systems as the future standard for the safe administration of complex genetic medicines.

Concurrently, there is a definitive transition toward scalable cGMP-compliant electroporation platforms engineered to maintain high transfection efficiency while satisfying rigorous regulatory standards for commercial manufacturing. As therapeutic programs advance from discovery to clinical application, firms are replacing manual techniques with automated physical delivery systems that ensure consistent performance across large production volumes, thereby mitigating the risk of batch variability. This growing reliance on validated, high-throughput instrumentation is evidenced by major technology adoptions within the sector; for example, MaxCyte entered into a strategic platform license with Legend Biotech in May 2024, granting rights to use its Flow Electroporation technology for the development of a diverse cell therapy portfolio. Such agreements emphasize the critical role of standardized, automated electroporation workflows in securing the supply chain for advanced cellular therapies.

Key Market Players

  • Thermo Fisher Scientific, Inc.
  • Promega Corporation
  • Lonza Group AG
  • QIAGEN NV
  • F. Hoffmann-La Roche Ltd.
  • Bio-Rad Laboratories Inc.
  • Merck KGaA,
  • OriGene Technologies, Inc.
  • MaxCyte, Inc.
  • Polyplus-transfection SA

Report Scope

In this report, the Global Cell Transfection Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cell Transfection Market, By Method

  • Electroporation
  • Lipofection
  • Calcium Phosphate
  • Viral Transfection
  • Others

Cell Transfection Market, By End User

  • Academic and Research Institutes
  • Pharmaceutical and Biotechnology Companies
  • Contract Research Organizations
  • Others

Cell Transfection Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell Transfection Market.

Available Customizations:

Global Cell Transfection Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cell Transfection Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Method (Electroporation, Lipofection, Calcium Phosphate, Viral Transfection, Others)
    • 5.2.2. By End User (Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Cell Transfection Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Method
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Cell Transfection Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Method
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Cell Transfection Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Method
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Cell Transfection Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Method
        • 6.3.3.2.2. By End User

7. Europe Cell Transfection Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Method
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Cell Transfection Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Method
        • 7.3.1.2.2. By End User
    • 7.3.2. France Cell Transfection Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Method
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Cell Transfection Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Method
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Cell Transfection Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Method
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Cell Transfection Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Method
        • 7.3.5.2.2. By End User

8. Asia Pacific Cell Transfection Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Method
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Cell Transfection Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Method
        • 8.3.1.2.2. By End User
    • 8.3.2. India Cell Transfection Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Method
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Cell Transfection Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Method
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Cell Transfection Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Method
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Cell Transfection Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Method
        • 8.3.5.2.2. By End User

9. Middle East & Africa Cell Transfection Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Method
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Cell Transfection Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Method
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Cell Transfection Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Method
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Cell Transfection Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Method
        • 9.3.3.2.2. By End User

10. South America Cell Transfection Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Method
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Cell Transfection Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Method
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Cell Transfection Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Method
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Cell Transfection Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Method
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Cell Transfection Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Thermo Fisher Scientific, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Promega Corporation
  • 15.3. Lonza Group AG
  • 15.4. QIAGEN NV
  • 15.5. F. Hoffmann-La Roche Ltd.
  • 15.6. Bio-Rad Laboratories Inc.
  • 15.7. Merck KGaA,
  • 15.8. OriGene Technologies, Inc.
  • 15.9. MaxCyte, Inc.
  • 15.10. Polyplus-transfection SA

16. Strategic Recommendations

17. About Us & Disclaimer